View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 7, 2018

FDA to support development of nicotine replacement therapies

The US Food and Drug Administration (FDA) has revealed plans to support the development of new nicotine replacement therapies to help eliminate addiction to combustible cigarettes.

The US F ood and Drug Administration (F DA) has revealed plans to support the development of new nicotine replacement therapies (NRTs) to help eliminate addiction to combustible cigarettes.

The public health agency aims to also create policies that will regulate the use of nicotine and tobacco in the country with a focus on implementing measures to help existing addicted smokers stop using combustible cigarettes.

Specifically, the F DA will work towards developing new forms of nicotine delivery that are in line with its public health goals.

F DA commissioner Scott Gottlieb said: “Part of this work requires that we recognise that nicotine, while highly addictive, is delivered through products posing a continuum of risk – with combustible cigarettes at one end, to nicotine replacement therapy (NRT) products at the other.

“We’re working on multiple fronts to recognise the role that more novel forms of nicotine delivery could play in achieving our public health goals, as part of an appropriately regulated marketplace.”

The F DA’s strategy includes new potentially less harmful tobacco products for adults who still want to use nicotine.

“We’re working on multiple fronts to recognise the role that more novel forms of nicotine delivery could play in achieving our public health goals.”

In addition, the regulator will closely monitor the overall approach to developing and regulating nicotine replacement therapies, which are designed in order to safely mitigate withdrawal symptoms.

Gottlieb added: “With novel forms of nicotine delivery being developed, it’s possible that new kinds of NRTs – with different characteristics or routes of delivery – can offer additional opportunities for smokers to quit combustible tobacco.”

The F DA has formed a Nicotine Steering Committee to assess new, evidence-based means for enabling use of therapeutic nicotine products against combustible tobacco.

In addition, the agency is considering the types of safety and efficacy studies required, along with the usage and labelling requirements for the new NRT products.

It has released two draft guidances to support the development of inhaled nicotine replacement therapies that could be submitted for approval as new drugs.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology